All episodes
Ep. 200 - Merck-Daiichi, Roche-Roivant, Base Editors
Ep. 199 - China Summit Preview
Ep. 198 - Novartis Finds Focus & EU Pharma Law
Ep. 197 - Mirati Takeout & 4Q23 Financial Markets Preview
Ep. 196 - CAR T's Next Act & Hudson's Vision for Sanofi
Ep. 195 - East-West Summit Preview
Ep. 194 - IPO Outlook & IRA Lawsuits
Ep. 193 - East-West CAR T Deals, Plus: Amgen-FTC
Ep. 192 - Tier-jumpers: a Back to School Overview
Ep. 191 - Circular RNA, Psychedelics, & Upcoming BioCentury Summits
Ep. 190 - Obesity Mechanisms, Noubar Takeaways, Scleroderma Platform Trial
Ep. 189 - Biogen-Sage Setback, Biotech IPOs, Sanofi Digital
Ep. 188 – Pharma deals; Plus: Genentech, Leerink Conversations
Ep. 187 - Alnylam-Roche; Plus: Insights on the IRA, FTC
Ep. 186 - 3Q Markets Preview, Donanemab & Lilly-Versanis
Ep. 185 - Leqembi's Launch, Biotech IPOs, Sarepta Approval
Ep. 184 - Califf's FDA reforms & Polaris' Schulman
Ep. 183 - EMA's Cooke, What's Next for IPSCs, & Leerink is Back
Ep. 182 - Merck’s IRA suit, Leqembi and MCEDs at ASCO
Ep. 181 - Highlights from ASCO
Ep. 180 - ASCO, Neuropsych & the IRA
Ep. 179 - DMD Gene Therapies, CBER & NIH
Ep. 178 - Live from Bio€quity, Part 2
Ep. 177 - Live from Bio€quity, Part 1
Ep. 176 - Bio€quity Europe 2023 Preview: Crafting a European Playbook for Success
Ep. 175 - Acelyrin IPO, Alzheimer's Data & Digital Endpoints
Ep. 174 - EC Pharma Law, ALS Biomarker, Astellas' Iveric Deal
Ep. 173 - EU VC Funds, Abortion Drug Ruling, IRA Insights
Ep. 172 - AACR Insights
Ep. 171 - 2Q Markets Preview, Abortion Drug Rulings, Gilead Oncology
Ep. 170 - Abortion Ruling & FDA; New VC Funds; IRA
Ep. 169 - FTC & Illumina, Plus: PCSK9s at SCOTUS
Ep. 168 - VCs' Take on SVB & New ALS Endpoint
Ep. 167 - The IRA, T Cell Therapies & The Distillery
Ep. 166 - SVB Shakeout: Next Steps for Biotech
Ep. 165 - SVB Fallout, Plus: Pfizer-Seagen
Ep. 164 - Viehbacher’s Vision, NK Cells & Bat Biotech
Ep. 163 - EU Pharma Law Overhaul, Abortion Drug Ruling, Dunn's Departure
Ep. 162 - New CMS Payment Models, China Markets Outlook, & Zhang's Latest Start-Up
Ep. 161 - New Cancer Paradigms, Distilling Innovations, & IPOs
Ep. 160 - Dose Optimization, Clinical Trials Diversity and QALYs
Ep. 159 - BIO's Priorities, ESG & Venture Trends
Ep. 158 - CAR T Manufacturing & Orphan Drugs
Ep. 157 - 2023 Markets Outlook & Buyside Picks
Ep. 156 - JPM Highlights & Alzheimer's Takeaways
Ep. 155 - U.K. Biotech, Aduhelm, 2022 Approval Trends
Ep. 154 - Madrigal in NASH, Moderna & Neoantigens, the Distillery
Ep. 153 - The Inflation Reduction Act
Ep. 152 - Amgen's Horizon Takeout. Plus: ASH, SERDs
Ep. 151 - Alzheimer's Takeaways, U.K. Biotech, Charles Forum
Ep. 150 - Model Term Sheets, Pragmatic Trials & Gene Therapy Prices
Ep. 149 - Takeaways from the East-West Summit
Ep. 148 - East-West Summit Highlights Part 2
Ep. 147 - East-West Summit Highlights Part 1
Ep. 146 - What's Next in Washington, Plus: SITC & the Distillery
Ep. 145 - What's Next for BIO, Plus: Pfizer, GSK
Ep. 144 - Alnylam's IRA Pause, Plus Argenx & Accumulus
Ep. 143 - East-West Summit Preview
Ep. 142 - Lundbeck, Biogen, Biden & Biomanufacturing, Nora Volkow
Ep. 141 - Neoantigen Vaccines, Drug Pricing, U.S.-China & U.K. Turmoil
Ep. 140 - Turbulence at BIO, Plus 4Q Preview & the Distillery
Ep. 139 - Wins in Neurodegeneration, U.S.-China & Life Science Cares
Ep. 138 - FDA User Fee Endgame, East-West Summit & Biogen
Ep. 137 - Intellia's Data, IRA's Orphan Impact, CFIUS Order
Ep. 136 - IRA, KRAS & ESMO
Ep 135 Pt. 5 - A Portrait of Biopharma's New Leaders
Ep 135 Pt. 4 - Filling Biopharma's Talent Pipeline
Ep 135 Pt. 3 - Rising Leaders & the VC View on Talent
Ep 135 Pt. 2 - CEOs in the Spotlight. Plus: Women Leaders, DEI
Ep 135 Pt. 1 - Back to School 2022 Overview
Ep. 134 - Preclinical Deal Making, Bluebird's Approval & Epigenome Editing
Ep. 133 - Financing Thaw? Plus: Protein Design & China Audits
Ep. 132 - M&A & Data: recipe for a rebound?
Ep. 131 - Seagen, New Modalities & Structure
Ep. 130 - Steady as a Roche. Plus: Washington Turbulence
Ep. 129 - Burr Bill, Novartis Makeover, ALS Update
Ep. 128 - Financial Markets Forecast, AAV Toxicity & Drug Pricing
Ep. 127 - TeneoTwo, Lightspeed, Arch & The Distillery
Ep. 126 - Growing Galapagos, Plus Abortion & Biopharma
Ep. 125 - Next Steps for ARPA-H
Ep. 124 - CRISPR's High Bar, Private Equity Inroads and the Distillery
Ep. 123 - Fixing FDA's Broken Advisory Panels
Ep. 122 - ASCO's Advances & Fixes for FDA's AdComms
Ep. 121 - ASCO, CRISPR IP & CStone
Ep. 120 - Next-gen NK cells, Plus Woodcock & BMS’s Russian Withdrawal
Ep. 119 - Bio€quity Recap, Part 2
Ep. 118 - Bio€quity Recap, Part 1
Ep. 117 - Sofinnova Partners’ Growth Deal, Plus Distillery on Tap
Ep. 116 - The Road to Bio€quity 2022: Navigating Through Talent & Capital Headwinds
Ep. 115 - FDA Reform on Deck, Plus Translation at Howard
Ep. 114 - Hutchmed Setback, FDA in Focus, HilleVax's IPO
Ep. 113 - Nkarta’s Breakthrough, Hatch’s Legacy & Shanghai’s Lockdown
Ep. 112 - Digesting DDR Data; Plus Sharpless’ Legacy, McKinsey’s Conflicts
Ep. 111 - Seeking Green Shoots Amid Biotech’s Gloom
Ep. 110 - Aduhelm’s Lessons, Plus Distillery Discoveries, Rare Disease Innovation
Ep. 109 - What's Next for Novartis? Plus: AACR, Merck KGaA
Ep. 108 - AACR Preview for CAR Ts in Solid Tumors; Plus FDA Weighs in on Data for ALS Ad Com
Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up
Ep. 106 - China's C-suite Hears FDA, Plus AACR, ARPA-H
Ep. 105 - War Pulls Biotech to Ukraine, Out of Russia